Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
ABN: 90 009 237 889
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
29 January 2013
PRIMA BIOMED TO PRESENT AT THE 15
ANNUAL BIO CEO & INVESTOR CONFERENCE
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
("Prima", "the Company") has announced today that Matthew Lehman, its Chief Executive
Officer, will present at the 15
Annual BIO CEO & Investor Conference on Tuesday, 12 February
2013 at 11:30am Eastern US Time in New York, NY. Mr. Lehman will provide an overview of the
Company and its corporate activities.
The presentation will be a live audio webcast and may be accessed by visiting Prima BioMed's
webcast will be available for 90 days following the presentation.
About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-
therapeutic products for cancer, Prima is dedicated to leveraging its current technology and
expertise to develop innovative treatment options for patients and to maximize value to
shareholders. Prima's lead product is CVacTM, an autologous dendritic cell product currently in
clinical trials for ovarian cancer patients who are in remission.
For further information please contact:
Ms. Jessica Brown, Prima BioMed Ltd.
+1 (919) 710-9061;
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574;
Mr. Axel Mühlhaus, edicto GmbH
+49 (0) 69 905505-52;